Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

942019

	registered interest
	date	16/07/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government whether they have carried out any research into the number of potential beneficiaries of a relaxation of the current restrictions on the use of medicinal cannabis.
	tabling member printed	Lord Bassam of Brighton
	uin	HL9533
	answer	answer is ministerial correction date of answer 25/07/2018 answer text <p>The Government has not commissioned research into the number of patients that might benefit from use of cannabis-based medicinal products.</p><p>The Government values the strong collaborative partnerships that we have across the European Union in the areas of science, research and innovation, and as part of exit negotiations is working to ensure that we have the best possible environment in which to support clinical trials and new medicines after we leave the EU. The Government will continue to monitor and share the emerging evidence on the therapeutic use of cannabis-based medicinal products.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL9534 question first answered 25/07/2018 11:46:44 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	3504 label Biography information for Lord Bassam of Brighton

942020

	registered interest
	date	16/07/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what plans they have to ensure that research into the use of medicinal cannabis as a potential treatment will be shared following the UK exiting the EU.
	tabling member printed	Lord Bassam of Brighton
	uin	HL9534
	answer	answer is ministerial correction date of answer 25/07/2018 answer text <p>The Government has not commissioned research into the number of patients that might benefit from use of cannabis-based medicinal products.</p><p>The Government values the strong collaborative partnerships that we have across the European Union in the areas of science, research and innovation, and as part of exit negotiations is working to ensure that we have the best possible environment in which to support clinical trials and new medicines after we leave the EU. The Government will continue to monitor and share the emerging evidence on the therapeutic use of cannabis-based medicinal products.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL9533 question first answered 25/07/2018 11:46:44 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	3504 label Biography information for Lord Bassam of Brighton

1136423

	registered interest
	date	02/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what plans they have, if any, to extend the availability of medicinal cannabis to people with diseases that cause chronic pain.
	tabling member printed	Lord Jones of Cheltenham
	uin	HL16873
	answer	answer is ministerial correction date of answer 10/07/2019 answer text <p>The law was changed on 1 November 2018 to allow clinicians on the General Medical Council’s Specialist Register to prescribe cannabis-based products for medicinal use (CBPM), where it is clinically appropriate and in the best interest of patients. Whilst the law allows clinicians to prescribe these products for the management of chronic pain, interim guidance jointly produced by the Royal College of Physicians and the Royal College of Radiologists, in liaison with the Faculty of Pain Medicine of the Royal College of Anaesthetists, concludes that there is not yet robust evidence for the use of CBPM in chronic pain, and their use is currently not recommended.</p><p>The National Institute for Health and Care Excellence (NICE) has been commissioned to develop updated clinical guidance on the prescribing of CBPM, including for the management of chronic pain, which will be published by October 2019. It will be based on the best available international evidence and will have been produced using NICE’s world-renowned process for identifying and assessing relevant studies and delivering such guidance. NICE is expected to consult on the draft guidance between 23 July – 20 August 2019.</p><p>An initial impact assessment <em>Rescheduling of cannabis-based products for medicinal use under the Misuse of Drugs Regulations 2001 </em>was published alongside The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018. A copy of this impact assessment is attached. This set out the approach that the Government proposed to take in assessing the costs and benefits of the change in the law at a population level, with regard to the rescheduling of CBPM. This framework included an analysis of cost and benefits for the use of cannabis for the management of chronic pain.</p><p>To further the evidence-base, the National Institute for Health Research has issued two calls for research in this area, and is working with the industry and researchers to ensure that the evidence is developed in a way that will inform decisions on public funding. This research will be open to all good quality proposals covering any indication, including multiple sclerosis, pain and other disorders unresponsive to existing treatments.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL16874 HL16875 question first answered 10/07/2019 15:30:08 answering member 4019 label Biography information for Baroness Blackwood of North Oxford attachment 1 file name Impact_Assessment.pdf title Impact_Assessment
	tabling member	248 label Biography information for Lord Jones of Cheltenham

1136424

	registered interest
	date	02/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what assessment they have made of (1) the advantages, and (2) the disadvantages, of allowing medical professionals to prescribe medicinal cannabis to people suffering from chronic pain.
	tabling member printed	Lord Jones of Cheltenham
	uin	HL16874
	answer	answer is ministerial correction date of answer 10/07/2019 answer text <p>The law was changed on 1 November 2018 to allow clinicians on the General Medical Council’s Specialist Register to prescribe cannabis-based products for medicinal use (CBPM), where it is clinically appropriate and in the best interest of patients. Whilst the law allows clinicians to prescribe these products for the management of chronic pain, interim guidance jointly produced by the Royal College of Physicians and the Royal College of Radiologists, in liaison with the Faculty of Pain Medicine of the Royal College of Anaesthetists, concludes that there is not yet robust evidence for the use of CBPM in chronic pain, and their use is currently not recommended.</p><p>The National Institute for Health and Care Excellence (NICE) has been commissioned to develop updated clinical guidance on the prescribing of CBPM, including for the management of chronic pain, which will be published by October 2019. It will be based on the best available international evidence and will have been produced using NICE’s world-renowned process for identifying and assessing relevant studies and delivering such guidance. NICE is expected to consult on the draft guidance between 23 July – 20 August 2019.</p><p>An initial impact assessment <em>Rescheduling of cannabis-based products for medicinal use under the Misuse of Drugs Regulations 2001 </em>was published alongside The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018. A copy of this impact assessment is attached. This set out the approach that the Government proposed to take in assessing the costs and benefits of the change in the law at a population level, with regard to the rescheduling of CBPM. This framework included an analysis of cost and benefits for the use of cannabis for the management of chronic pain.</p><p>To further the evidence-base, the National Institute for Health Research has issued two calls for research in this area, and is working with the industry and researchers to ensure that the evidence is developed in a way that will inform decisions on public funding. This research will be open to all good quality proposals covering any indication, including multiple sclerosis, pain and other disorders unresponsive to existing treatments.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL16873 HL16875 question first answered 10/07/2019 15:30:09 answering member 4019 label Biography information for Baroness Blackwood of North Oxford attachment 1 file name Impact_Assessment.pdf title Impact_Assessment
	tabling member	248 label Biography information for Lord Jones of Cheltenham

1136425

	registered interest
	date	02/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what studies (1) have been carried out, and (2) are proposed, to investigate the pain relief impacts of medicinal cannabis on people who have multiple sclerosis.
	tabling member printed	Lord Jones of Cheltenham
	uin	HL16875
	answer	answer is ministerial correction date of answer 10/07/2019 answer text <p>The law was changed on 1 November 2018 to allow clinicians on the General Medical Council’s Specialist Register to prescribe cannabis-based products for medicinal use (CBPM), where it is clinically appropriate and in the best interest of patients. Whilst the law allows clinicians to prescribe these products for the management of chronic pain, interim guidance jointly produced by the Royal College of Physicians and the Royal College of Radiologists, in liaison with the Faculty of Pain Medicine of the Royal College of Anaesthetists, concludes that there is not yet robust evidence for the use of CBPM in chronic pain, and their use is currently not recommended.</p><p>The National Institute for Health and Care Excellence (NICE) has been commissioned to develop updated clinical guidance on the prescribing of CBPM, including for the management of chronic pain, which will be published by October 2019. It will be based on the best available international evidence and will have been produced using NICE’s world-renowned process for identifying and assessing relevant studies and delivering such guidance. NICE is expected to consult on the draft guidance between 23 July – 20 August 2019.</p><p>An initial impact assessment <em>Rescheduling of cannabis-based products for medicinal use under the Misuse of Drugs Regulations 2001 </em>was published alongside The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018. A copy of this impact assessment is attached. This set out the approach that the Government proposed to take in assessing the costs and benefits of the change in the law at a population level, with regard to the rescheduling of CBPM. This framework included an analysis of cost and benefits for the use of cannabis for the management of chronic pain.</p><p>To further the evidence-base, the National Institute for Health Research has issued two calls for research in this area, and is working with the industry and researchers to ensure that the evidence is developed in a way that will inform decisions on public funding. This research will be open to all good quality proposals covering any indication, including multiple sclerosis, pain and other disorders unresponsive to existing treatments.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL16873 HL16874 question first answered 10/07/2019 15:30:09 answering member 4019 label Biography information for Baroness Blackwood of North Oxford attachment 1 file name Impact_Assessment.pdf title Impact_Assessment
	tabling member	248 label Biography information for Lord Jones of Cheltenham

1052543

	registered interest
	date	01/02/2019
	answering body	Home Office
	answering dept id	1
	answering dept short name	Home Office
	answering dept sort name	Home Office
	hansard heading	Cannabis: Medical Treatments
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government how many applications for licences to cultivate cannabis for medicinal purposes in the UK they have received since 1 January 2016.
	tabling member printed	Lord Wasserman
	uin	HL13376
	answer	answer is ministerial correction date of answer 14/02/2019 answer text <p>No licences have been issued to cultivate cannabis for medicinal purposes. Licences are issued to cultivate High THC cannabis for research and/or the extraction of cannabinoids.</p> answering member printed Baroness Williams of Trafford grouped question UIN HL13377 HL13378 question first answered 14/02/2019 17:27:41 answering member 4311 label Biography information for Baroness Williams of Trafford
	tabling member	4207 label Biography information for Lord Wasserman

1052544

	registered interest
	date	01/02/2019
	answering body	Home Office
	answering dept id	1
	answering dept short name	Home Office
	answering dept sort name	Home Office
	hansard heading	Cannabis: Medical Treatments
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government how many licences for the cultivation of cannabis for medicinal purposes they have (1) granted, and (2) refused since 1 January 2016.
	tabling member printed	Lord Wasserman
	uin	HL13377
	answer	answer is ministerial correction date of answer 14/02/2019 answer text <p>No licences have been issued to cultivate cannabis for medicinal purposes. Licences are issued to cultivate High THC cannabis for research and/or the extraction of cannabinoids.</p> answering member printed Baroness Williams of Trafford grouped question UIN HL13376 HL13378 question first answered 14/02/2019 17:27:41 answering member 4311 label Biography information for Baroness Williams of Trafford
	tabling member	4207 label Biography information for Lord Wasserman

1052545

	registered interest
	date	01/02/2019
	answering body	Home Office
	answering dept id	1
	answering dept short name	Home Office
	answering dept sort name	Home Office
	hansard heading	Cannabis: Medical Treatments
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government which applicants have been granted a licence to cultivate cannabis for medicinal purposes in the UK since 1 January 2016.
	tabling member printed	Lord Wasserman
	uin	HL13378
	answer	answer is ministerial correction date of answer 14/02/2019 answer text <p>No licences have been issued to cultivate cannabis for medicinal purposes. Licences are issued to cultivate High THC cannabis for research and/or the extraction of cannabinoids.</p> answering member printed Baroness Williams of Trafford grouped question UIN HL13376 HL13377 question first answered 14/02/2019 17:27:41 answering member 4311 label Biography information for Baroness Williams of Trafford
	tabling member	4207 label Biography information for Lord Wasserman

1174248

	registered interest
	date	29/01/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what his Department's policy is on the availability of medicinal cannabis; and if he will list the medical conditions that the NHS treats with medicinal cannabis.
	tabling member constituency	Vale of Glamorgan
	tabling member printed	Alun Cairns
	uin	9664
	answer	answer is ministerial correction date of answer 05/02/2020 answer text <p>On 1 November 2018, the law was changed to allow clinicians on the General Medical Council’s (GMC) Specialist Register to prescribe cannabis-based products for medicinal use, where clinically appropriate and in the best interests of patients. The law does not restrict the medical conditions for which these products may be used, and the decision of whether to prescribe is ultimately one for clinicians to make on a case by case basis.</p><p> </p><p>Two reviews have taken place since this change in the law:</p><p> </p><p>- On 8 August 2019, NHS England and NHS Improvement published its review into barriers to accessing cannabis-based products for medicinal use on NHS prescription which is available at the following link:</p><p><a href="https://www.england.nhs.uk/publication/barriers-to-accessing-cannabis-based-products-for-medicinal-use-on-nhs-prescription/" target="_blank">https://www.england.nhs.uk/publication/barriers-to-accessing-cannabis-based-products-for-medicinal-use-on-nhs-prescription/</a></p><p>- On 11 November 2019, the National Institute for Health and Care Excellence (NICE), following a review of the available evidence, published guidance on the prescribing of cannabis-based medicinal products which is available at the following link:</p><p><a href="https://www.nice.org.uk/guidance/ng144" target="_blank">https://www.nice.org.uk/guidance/ng144</a></p><p>This demonstrates a clear need for more evidence to support prescribing and funding decisions of cannabis-based medicines for intractable nausea and vomiting; chronic pain; spasticity; and severe treatment-resistant epilepsy.</p><p>We continue to work hard with the health system, industry and researchers to improve the evidence base for cannabis-based medicines and to implement the recommendations of NHS England and NHS Improvement’s review.</p><p> </p><p> </p><p> </p><p> </p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 9665 question first answered 05/02/2020 13:52:28 answering member 4380 label Biography information for Jo Churchill
	tabling member	4086 label Biography information for Alun Cairns

1174251

	registered interest
	date	29/01/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what plans he has to review his policy on the prescribing of medicinal cannabis.
	tabling member constituency	Vale of Glamorgan
	tabling member printed	Alun Cairns
	uin	9665
	answer	answer is ministerial correction date of answer 05/02/2020 answer text <p>On 1 November 2018, the law was changed to allow clinicians on the General Medical Council’s (GMC) Specialist Register to prescribe cannabis-based products for medicinal use, where clinically appropriate and in the best interests of patients. The law does not restrict the medical conditions for which these products may be used, and the decision of whether to prescribe is ultimately one for clinicians to make on a case by case basis.</p><p> </p><p>Two reviews have taken place since this change in the law:</p><p> </p><p>- On 8 August 2019, NHS England and NHS Improvement published its review into barriers to accessing cannabis-based products for medicinal use on NHS prescription which is available at the following link:</p><p><a href="https://www.england.nhs.uk/publication/barriers-to-accessing-cannabis-based-products-for-medicinal-use-on-nhs-prescription/" target="_blank">https://www.england.nhs.uk/publication/barriers-to-accessing-cannabis-based-products-for-medicinal-use-on-nhs-prescription/</a></p><p>- On 11 November 2019, the National Institute for Health and Care Excellence (NICE), following a review of the available evidence, published guidance on the prescribing of cannabis-based medicinal products which is available at the following link:</p><p><a href="https://www.nice.org.uk/guidance/ng144" target="_blank">https://www.nice.org.uk/guidance/ng144</a></p><p>This demonstrates a clear need for more evidence to support prescribing and funding decisions of cannabis-based medicines for intractable nausea and vomiting; chronic pain; spasticity; and severe treatment-resistant epilepsy.</p><p>We continue to work hard with the health system, industry and researchers to improve the evidence base for cannabis-based medicines and to implement the recommendations of NHS England and NHS Improvement’s review.</p><p> </p><p> </p><p> </p><p> </p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 9664 question first answered 05/02/2020 13:52:28 answering member 4380 label Biography information for Jo Churchill
	tabling member	4086 label Biography information for Alun Cairns